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O&&es. The specific objective of the REDUCE trial was to in the incidence of mqjor adverse events [i.e., death, myoeordial 
evaluate the e&t of low molecular weight beparin on the ioci- inlnrction, need for rtintelveotion or bypass surgery]). absolute 
dence and occurrence of resteaoris in patients undergoing pem- loss of minimal lumen diameter and incidence of restenosis 
tamous traasluminal camnary sngioplasty (PITA). during the obsemation period of 30 w&s alter PTCk 
lhkgmfd. Uafractionated hepariu and its low molecular 
weight fkagments possess rntiproliferative elerts and bave been 
showntomhcenmintlmalsnmoUtmuseleceUmigotioaand 
pmlilwPtlonlnN!spMsetovascaku~ln~tdstndks 
h&h&. The REDUCE trial is an international prospective, 
randomized, double-blind, multicenter study. Twenty-six centers 
in Eumpe and Canada enmlled 625 patients rvilh single-lesion 
comnay altely obsmctions sultabk tbr PTCA The knndltd 
six patlents received K!viparin as a 7,~u bdus beeore tW#& 
foRowed by lO,!%O U as an infiudon over 24 h and then twicedaily 
3$00-U snbcutaa4~s application for 28 days. I%e 306 patients in 
the control gmup received a bolus of lO,WO U of unfractionrted 
hepario followed by an inf’usioo of 24,000 U over 24 h. These 
patients then undenrent 28 days of subcutall~~ll~ placebo injec- 
tions. The primary end points welp eSiaq (defined as a reduction 
Resuhs. Using the intention to treat analysis for all patients. 
102 (33.3%) in tbe reviparin group and 98 (32%) in the control 
group have rracbed a primary clinical end point (Rlative risk 
[RR] 1.04,95% conthlence intemal ICI] 0.83 to 131. p = 0.707). 
Likewise, no dilerence in late loss of minimal lumen diameter was 
evident for both groups. Acute events within 24 h oceuned in I2 
p&W (3.9%) in the reviparin gmup and 25 (8.2%) in the control 
gmup (RR 0.49, 95% Cl 0.26 10 0.92. p = 0.027) during or 
immediately after the initial pmcedure. lo the control group. eight 
major bleeding complications occurrod, and in the mviparin 
group, seven were observed within 35 days after PITA. 
Cunc/i~~ians. Reviparin use during and after coronary angio- 
plasly did not lPduce the occulTence of mqjor clinical events or the 
incidence of angiographic restenosis over 30 weeks. 
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Since the introduction of pert ltaneous transluminal coronq 
angioplasty (PTCA) in 1977 (l), this method has shown 
impressive clinical results in the acute setting. Increased expe- 
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rience and rapid advances in tcchnoloby have resulted in a 
primary success rate of up to 95%. However. late restenosis, 
which constitutes the most important problem after successful 
angioplasty. continues to occur in 308 to 50% of patients 
within 3 to 6 months (2-5). Experimental and human postmor- 
tern studies have shown (6.7) that the process of restenosis is at 
least in ,part due to neointimal proliferation. Although the 
incidence, timing, clinical. anatomic and pathophysiologic fac- 
tors associated with restenosis have been studied in depth 
(g-14). rtjost medical attempts to reduce the occurrence of 
restenosis thus far have failed. 
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Unfraitionated heparin has long been known as an effective 
anticoagulani with inhibitory action on platelet function and an 
additional effect on smooth muscle cell proliferation. In recent 
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have been shown to be as etTective and safer than unfraction- 
ated heparin in the prevention and treatment of venous 
thromboembolism (15,16). Reviparin is a new low molecular 
weight heparin with anticoagulatory efficacy comparable to 
unfractionated heparin and a better safety profile than unfrac- 
tionated heparin (3.18). In vitro studies with reviparin have 
shown significant inhibition of smooth muscle cell migration 
and proliferation in human cell cultures without affecting 
endothelial cell growth (19). Experimental studies in New 
Zealand rabbits (20) revealed that the extent of intimal mitosis 
during the first 7 days after PTCA was significantly reduced 
(p < 0.01 at 3 days; p < 0.0s a! 7 days) after injections of 
reviparin (2.5 mg/kg body weight per day subcutaneously, 
ivhich corresponds to 400 anti-Xa U/kg per day), resulting in 
only a moderate increase in intimal wall thickness after 28 days 
compared with that in a control group treated with unfraction- 
ated heparin. In a pishminary open clinical pilot trial con- 
ducted to evaluate the safety of reviparin application in the 
clinical setting, no increased bleeding complications were 
observed (21). 
The purpose of the randomized. double blind, placebo- 
controlled, multicenter REDUCE trial (Reduction of Resten- 
osis After PTCA, Early Administration of Reviparin in a 
Double-Blind, Unfractionated Heparin and Placeb&ontrolled 
Evaluation) was to evaluate whether reviparin given intraarte- 
rially and intravenously during PICA and subsequently sub- 
cutaneously twice daily for 28 days after PTCA in a dosage 
equivalent to that used in the animal experiments (211) and 
compared with unfractionated heparin and placebo would 
reduce the incidence of restenosis, as determined by the 
occurrence of major clinical events and angiography. 
Methods 
!Mectioa of patients. Patients scheduled to undergo single- 
lesion coronary angioplasty (PTCA) because of stable or 
unstable angina (except for class 3C as defined in the Braun- 
wald classification) were eligible for the study if they had no 
history of bleeding disorders, recent active bleeding, uncontrolled 
asthma or hypertension (blood pressure ‘>180/105 mm Hg), 
active peptic ulcer disease, history of heparin-associated 
thrombocytopenia. acute myocardial infarction withiri 14 days 
and unstahle angina requiring continuous heparin therapy. 
Patients had to have been suitable candidates for coronary 
bypass surgery.’ A left main coronary artery atenosis >50%, 
angioplasty of saphenous vein graft or previous PTCA at the 
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same lesion site also were exclusion criteria. The study was 
carried but according to tht principles of the Declaration of 
Helsinki and the Guidelines for Good Clinical Practice based 
on a study protocol..Written informed consent according to 
local practice tias obtained for every patient. 
Randomizcition. Patients were randomly assigned to either 
reviparin or unfractionated heparin plus placebo treatment. 
The randomization was realized at the centers by blinded, 
prepacked medication sets with ascending numbers. To ensure 
an equal distribution of ‘treatments in each center, a block 
randomization procedure on a site basis in blocks of 12 
treatment assignments was used. Patients were screened be- 
hveen May 1993 and June 1994. Six hundred twenty-five 
patients were enrolled at 22 European and 4 Canadian centers 
(see Appendix). 
Study protocol. Standard balloon angioplasty was per- 
formed through the transfemoral approach using an 8F guide 
catheter according to standard techniques. At the time of arterial 
access. either a bolus of unfractionated heparin (10,000 IV) 
or reviparin (7,ooU IU anti% U) was injected into the femoral 
sheath. Subsequently, all patients received an intravenous 
infusion of either unfractionated heparin (24,Wl IU) or 
reviparin (10,500 IU anti-Xa U) over 16 2 4 h (mean + SD). 
Aspirin (100 mgiday) was administered 1 day before and 
throughout the treatment period. Beginning on the evening of 
day 1. either 3,500 IU anti-Xa U oi reviparin or placebo was 
administered subcutaneously twice daily for 28 days. 
The clinical follow-up visit was scheduled 4 and 30 weeks 
after angioplasty for clinical and laboratory assessment. Laho- 
ratory assessment included complete blood count, coagulation 
profile and liver function tests. The global clotting tests 
(activated prothrombin time, thromboplastin time end anti-Xa 
plasma level) were analyzed at core laboratory (Sainte Marie, 
Paris, France for the European centers; McMaster University 
Medical Center, Hamilton, Ontario for the Canadian centers). 
Patient compliance with regard to subcutaneous injections was 
assessed by a paticr,t booklet to be filled out and the measured 
anticoagulation levels after 28 days. To assess angiographic 
restenosis, repeat coronary angiography was performed at 
26 2 2 weeks after PICA through the femoral sheath with a 7F 
femoral diagnostic catheter after readjustment of the X-ray 
gantry angular settings and the various height levels, according 
to values previously documented during the original interven- 
tion. 
The angiograms were sent to the core angiographic labora- 
tory for further blinded analysis. To standardize the method of 
data acquisition and to ensure the exact reproducibility of the 
angiograms acquired after intervention and follow-up, mea- 
surements were made using the Coronary Artery Analysis 
System, as ‘described elsewhere (22). Ten ,percent of the 
ingiograms w&e reanalyzed in blinded mannkr as part of the 
quality control assessment. 
Study fad points. The.pimary clinical end point was de- 
fined as the first occurrence of any of the following events in 
the first 30 weeks after the initial procedure: death from any 
cause; nonfatal myocardial infarction; clinically driven repeat 
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revascularization of the. initial treatment vessel, including 
intervfzntions using an -alternative percutaneous revasculariza- 
tion device. coro?ary artery by&ss surgery’or implantation of 
a coronary stent as a bailout procedure. Rescut-sient implan- 
tation was defined as the placement of a stent in the event of 
flow reduction to Thrombolysis in Myocardial Infarction 
(TIMI) grade 0 or 1. All emergency stent implantations were 
checked for the eligibility of the rescue criterion by the central 
angiographic committee. 
hfyxatdial infarction was defined as documented elevation 
of serum creatine kinase levels to greater than twice the upper 
limit of normal for the laboratory; electrocardiographic 
changes indicative of myocardial infarction; o: typical angina1 
pain at rest prolonged for >30 min despite administration of 
nitroglycerin. 
The prinwry angiograp/~ic end point was defined in terms of 
absolute loss in minimal lumen diameter at the diiated site 
from after IWA to follow-up an;iography (median fo,low-up 
of 184 days after FTCA) assessed by quantitative coronary 
analysis. Restenosis was defined as loss of >504 of the initial 
gain of PTCA, according to the National Heart. Lung, and 
Blood Institute (NHLBI) 4 definition. 
The safety of the trial medication and the feasibility of 
replacing standard heparin during the intervention was as- 
sessed in terms of occurrence of bleeding complications or 
other adverse events that could be attributed to the trial 
medication. In addition, bleeding was quantified as major or 
minor. Major bleeding was defined as a clinically evident 
bleeding episode associated with a decrease in hemoglobin of 
al least 2 g/dl or requiring transfusion of at least 2 U of blood. 
or both. Any intracerebral or retroperitoneal bleeding was 
considered a major episode. The site and source of bleeding 
episodes were noted. 
D&I Nt and statIstIcal snaIpis. The primary 
variable for biometric clinical evaluation was the incidence of 
clinical events. as previously already defined. On the basis of 
data from previous trials (23). this trial was planned to include 
a minimum of 281 patients/group to detect a reduction of 40% 
in the primaty clinical end point (the event rate in the control 
group was predicted to be 30%. with alpha = 0.05. beta = 0.1 
[two-tailed Fisher exact test]). All data were monitored hy the 
Data and Statistical Coordinating Center (clinical data) or the 
core laboratory (angiographic data) as well as the monitoring 
team of the trial sponsors. The Data and Statistical Coordinat- 
ing Center performed the final statistical analysis. 
The results of the two treatment groups were displayed as 
Kaplan-Meier survival curves (24). For the primary end point, 
a Mantel-Haenszel test was performed using the end point 
rates in the two treatment groups until the end of week 30. This 
analysis involved all randomized patients with the exception of 
I3 patients who did not receive study medication, according to 
the intention to treat principle. The primary angiographic end 
point was statistically evaluated by comparison between the 
two treatment groups with respect to loss of minimal lumen 
diameter from after PTCA to the 26 tieek follow-up visit and 
was performed according to the intention to treat principle for 
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Tabk 1. Bawli& Clinical CharaCtcristics of lntcntion to ,, 
Tirat Cohort 3. 
L‘FH Placrho’ Rcvipuin Tn1al 
(n = 311ht (n = 36) ,(? = 612) 
]no. (5 t] (nn. (‘C )I Inn. lri)l 
-- -. - 
hlalc 3x (IN?) 2.w (M.3) Slh (X4.3) 
Wan (:SI)) a+- (yrj 57.0 f 9.4 sn.1 z u.s SK.2 z 9,s 
Ribk firctor~ 
Diatwcs mellitus 37fE.I) 32 ( IfI.5 ) 69 (11.3) 
H~gxrwnsitm 103 (33.7) Ill3 (33.7) xlh (32.7) 
Hpxcholestcrolemia I49 (48.7) 154 (4Y.o) -39 (48.9) 
Histoy of smoking’ x4 (66.7) 21’) i71.h) 423 (69.1) 
Prcritas MI 13?(43.1) IX (43.1) ?M (43.1) 
Angina C&IS\ (KS) 
None 17 (Ml) IX (S.U) 3s (5.7) 
I 511 (Ih.3) 44 (WI) 94 (1.4) 
II IUY (35.h) I?4 (4ll.S) 133 (3X.1) 
Ill 6x (2.2) h? (2ll.1) 130 (?I.?) 
IV V(lX.6) 5.5 (NO) ll?(IH.3) 
Mitiing s (1.6) 3 (1.u) X(1.3) 
‘History and currcnl smokers. CCS = Canadian Cardiwwulsr Swiety: 
MI = mptrardial infarction: UFH = unfrac~ionalcd hrprin. 
514 patients for whom all three angiograms were available. 
Continucus variables are expressed as mean value %SD and 
were compared in the treatment group: using covariance 
techniques with center and haseline values as covariates. The 
Mantel-Haenszel test stratified for centers was used to com- 
pare proportions. Discrete variables are expressed as counts 
and percentages as well as relative risk with 9S9 confidence 
interval. with respect to treatment groups. Comparisons among 
treatment groups with respect to all other variables excluding 
the primary clinical end point wc;c made for descriptive 
purposes. Dsta are presented with nominal two-tailed p values 
(unadjusted for multiple comparisons). 
Results 
The intention to treat patient group included all patients 
who received at least one dose of the study medication. The 
clinical “per protocol” paricnt group included all compliant 
patients of the intention to treat clinical cohort who had an 
initial single-vessel single-lesion FTCA and a complete clinical 
follow-up. Three hundred six patients were randomized to 
receive unfractionared heparin/placebo and 306 to receive 
reviparin. Clinical or telephone follow-up for evaluation of the 
primary clinical end point was obtained for 601 patients. 
During the course of the study. eight patients were lost to 
follow-up, and three had their second follow-up visit before the 
end of week 30. and no telephone evaluation of the end point 
Was obtained. The +aseiitie characteristics of the intention to 
treat cohort are given in Tables I and 2. The two treatment 
groups did not differ III sny baseline clinical or angiographic 
characteristics. In general, patients had one-vessel disease. and 
a single lesion was dilated in all patients according to the 
inclusion criteria. Comparison of baseline characteristics in the 
per protocol patient group also showed, no dilIerence in any 
1Wl KARSCH ET AL. 
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baaline characteristic. Ninety-three patients in the control 
group and 7Y in the reviparin group were excluded from the 
per protocol analysis. The primary reason for exclusion was 
insuficient compliance with the 6-month follow-up visit or 
missing protocol compliance. Nineteen patients did not meet 
entry criteria (Table 3). The mean dose of intravenous infusion 
was 92.164 for the control group and 93.05G for the reviparin 
group. Comparable compliance was observed for the adminis- 
tration of the subcutaneous injections. 
Primary dicacy analysis. Using the intention to treat 
analysis (Table 4). treatment failure, as defined by the occur- 
rence of death, myocardial infarction. bypass surgery and 
emergency or elective repeat PTCA in the observation per&f. 
was 33.3% for the rcviparin group and 32% for the control 
group (relative risk [RR] 1.04, 95% confidence interval [Cl] 
0.83 to 1.31. p = 0.707) (Table 4). Angiographic restenasis 
using the NHLBI 4 definition was present in H6 (.34.4’1;,) 
patients m the control group and in 89 (33%) in the reviparin 
group. Only 61 (19.9%) patients in the control group and 5U 
(16.4%) in the reviparin group developed significant angina 
requiring repeat coronary angiophsty. indicating that a certain 
percentage of patients had aymptcmatic restenosis. The occur- 
rence of death and myocardial irlfarction was an infrequent 
event (2.6% in the control group [13 patients] and 4.5% [8 
patients] in the reviparin group). Subsequent revascularization 
with bypass surgery or angioplasty was performed in 69 
(22.6%,) of the patients in the control group and in 81(26.8%1) 
of the patients in the rcviparin group. 
However, acute cvcnls during or immediately after the 
procedure- (day 1) ‘occurred in 12 (3.9%) pati$nts in the 
reviparin group and in 25 (8.2%) of the control group (RR 
0.49,95% Cl 0.26 to 0.92, p = 0.027) (Fig. 1). Emergency stent 
implantation in the acute stage was riiffcrent in the two groups 
(21 patients in the control group vs. 6 in the reviparin group; 
RR 0.29, 95% Cl 0.13 to 0.66, p = 0.03). Autoperfusion 
balloons in the event of TIMI perfusion grade 0 or 1 after 
angioplasty were used in 16 patients in the control group and 
JACC Vol. X No. 6 
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Table 3. Rcawns ftjr Exclusion From Per Protwxl Cohort 
t:FH Placclw Rn-iparin Tnlal 
(n x 3uh) Ill = 3061 (n = 612) 
_ Ino (:;)I [no. t’;)] [no. ((;)I - -- 
Lml Ill fOIlON -up s (2.h) 3(1.01 II (IX) 
Inawrcrl wiry crilrria’ 1-l 14.tl) S(l.h) lY(3.ll 
Pnm~~l \iAli~ln IS (5.Y) 1’fL.W 35 (5.7) 
Olhcr 
I~clll~w”p I&W 1.11~ .l3ll4 I) 40(13 1) A3(1h, 
No halicwn dilaliun pcrbrmod 5 (1.h) I I (3.h) lb(!6) 
Cwwnt withdrawn during srud) 5 1: 6j ?(].I)) X(1.3) 
T0laI cnclutinns 93130.4) 79(z5 81 17?(Xl) 
‘Patients not mccling flxrccl inclusion criteria al wxmd review. UM = 
unrraclwnatcd hcprrin. 
in Y in the reviparin group (RR U.ClY. Y5? Cl 0.24 to 1.12. p = 
U.U96). Nonfatal myocardial infarction occurred in three con- 
trol group patients and four reviparin group patients subse- 
quently after PKA. and an emergency repeat PTCA was 
performed in one control group anti two revlparin group 
patients. Analysis of primary end points after 30 weeks was 
additionally done for the per protocol clinical group. Major 
clinical events occurred in 64 patients (30%) in the control 
group and in 72 patients (31.7%) in the reviparin group (RR 
1.03. 95% CI 0.78 to 1.36, p = 0.84). 
Angiogtaphic analysis. The change in minimal lumen and 
reference diameters before and after PTCA and at the 
h-month follow-up visit were assessed for all patients in whom 
follow-up angiography was available (n = 514). The mean 
acute gain in minimal lumen diameter was 0.84 mm for the 
control group and 0.88 mm for the reviparin group. The mean 
late loss in minimal lumen diameter was 0.25 and U.2Y mm. 
respectively (p = 0.55, analysis of covariance). The cumulative 
distribution of the minimal lumen diameter before and imme- 
diately after FTCA and at follow-up angiography likewise 
showed no difference between the two groups and followed a 
gaussian distribution. 
Bleeding romplkatlons. No substantial differences were 
found in the rate of major bleeding complications: 8 patients 
(2.6%) in the control group vs. 7 patients (2.3%) in the 
reviparin group (RR 0.88, 95% CI 0.32 to 2.41, p - 0.8). All 
major bleeding episodes occurred within 35 days after PTCA. 
There was one episode of intracerrbrsl and one of intraocular 
bleeding in the reviparin group, and all except rhrec major 
bleeding episodes in the contml group occurred a1 the femoral 
arterial entry sheath (Table 5). 
Discussion 
The results of the present study demonstrate that rcviparin 
did not reduce adverse clinical outcome or the occurrence of 
angiographic restenosis compared with unfractionated heparin/ 
placebo over a period of 6 months. 
E&cts of heparia and its low decular weight fractions. 
Heparin is used routinely during angioplasty to reduce the risk 
of a thrombotic abrupt vessel closure. However, it is also well 
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Tabk 4. Prima0 Clinical End Poinrs in Trcatmcnt Groups 
Evrnl 
Primary end point 





Rrscue stem implanwion 





Unkmwn end poinl sfrtu%t 
known, at least in the experimental setting, to have antiprolif- 
erative actions that may be useful in the prevention of reste- 
nosis (25-B). Cell culture data demonstrated that the dose- 
dependent antiproliferative properties of low molecular weight 
heparins are more potent and are basically independent of 
their ability to bind antithrombin III (29). Although the exact 
mechanism oi action of heparin and its low molecular weight 
fractions for prevention of cell proliferation is not fully under- 
stood, the antipmliferative effect of heparin and its analogues 
appears to be due to the inhibition of thymidine and uridinc 
uptake by smooth muscle cells (26). It is assumed that the 
glycusaminoglycans provide an important cell regulatory action 
Ffgue 1. Plot of occurrence of clinical cvcnts (end points) in the 
unhadionated hcparin (UFH)/Placet~ an:1 ruviparin group within 
WI days of PKA. 
within the arterial wall (27). Reviparin. a low molecular weight 
heparin. differs from unfractionatcd hrparin in a numher of 
ways (30). It is generated from hcparin by chemical depoly- 
merization and has an average molecular weight of 4,300 
daltons. The depolymerization process produces widely differ- 
ent products with differences in their microstructure, anti- 
thrombin III affinity and the degree of sulfation. Because of the 
shorter chain length. it has approximately three times more 
anti-Xa activity than anti-lla activity in contrast to the I:1 ratio 
for heparin. 
Experience with heparins in reducing rpstcnosis. Attsmpts 
to modify the tihroproliferdlive rrsponse due to angioplasty by 
pharmacologic interventions have yielded very limited success. 
Ellis ct al. (31) reported that an 1% to 24-h infusion of heparin 
after PTCA did not prevent restenosis in a randomized trial. In 
one study (32) using fragmin, a low molecular weight heparin, 
a significant trend toward a reduction in restenosis was seen. A 
p,:eliminary brief report (31) of a randomized trial of lO.ooO U 
oi subcutaneous heparin once daily compared with placebo 
kas discontinued because of a high incidence of adverse events 
and angiographic restenosis. One report (33) has even sug- 
gcstcd that hcparin treatment may promote restenosis. Enox- 
aparin in a dose of 40 mg/day subcutaneously for I mnnth did 
not reduce the incidence of angiographic restenosis or the 
occurrence of clinical events over 6 months (-34). 
Study tIesIgn. In view of this previous experience. several 
aspects of the REDUCE trial are noteworthy. The selection of 
patients with single-lesion dilation was designed to avoid 
confusion’ resulting fmm differences in per patient and per 
lesion rysults. Patients with restenosis or myocardial infarction 
within 14 days of PTCA were ‘excluded to first define the 
impact of the substance in a population with comparable 
pathophysiologic substrates. The pharmacologic regimen was 
based on similar experimental designs, and the dosage was 
adjusted according to the dosage that’resulted in a significant 
reduction of smooth muscle cell proliferation i? the expexi- 
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T&k 5. B&ding Complications and Injccfion Site Hcmorrhsgc in Intention to Treat Cohort 
UFH Pklcehn Rsviparin T01al 
i’ (n -= 31) (n .: 306) (n = hi!) 
Event ]nll. (‘i I] (rw. (5)] [no. (‘;)I p Value’ 
Maior trlcding within 35 da!s rf(cr PICA 8 (33) 7 (23) 15 (2.5; O.ti 
lnjc&n site hcmorrhagc !h (R.5) 12(3(r) 3x (Il.!) Imht; 
Dccrerse in hem+hin ?! g JI+ h2(211.3) 3(II.JI Y7 1 IL%) II.1Yl? 
‘Mann+Hrcnucl tn!. controlling for rcntcr. ?Twcntv-one p;nicnr\ (II in rhc unfr:rrticmatrd hepsrin placclw group. 
I) in rhc reviparin group) with mrwnp I.uwr:norv rlara ,Ahhrevi~(ionv a\ in Tahl~ 1 and .l 
mental setting (16). Despite the high dosages necessary for the 
antiprolif..,..., Wyl.., . ..- ..SII.--.-_ .,_- .-r-tkm niX=~n the cnhct-mre wsr y-!! !&=ratryrj at this 
dosage. without the occurrence of increased bleeding compli- 
cations. It is of major clinical interest that no monitoring was 
ncedcd to follow the trcatmcnt with rcviparin. According to 
the cxperimcntally documented time course of smooth mmsclc 
ccl1 proliferation after vascular injury (H), a specific delivery 
protocol was adopted. Rccausc the process of smooth muscle 
cell proliferation begins with the onset of injury and continues 
for at lcast 2 weeks. treatment with reviparin was started early 
and was maintained for a su5icient length of time. 
Reasons for lark of benefit. There are many potential 
reasons for the lack of an effect of reviparin on restenosis: 1) 
Systemically or subcutaneously injected doses might not have 
been sufficient to reduce the local arterial proliferative actions. 
To further svaluate this option. local application with specific 
local delivery systems (35-37) as well as trials using hcparin- 
coated stems (38) are in the expcrimcntal and early clinical 
stages. 2) The lack of benefit to date shown in nearly all clinical 
trials of drugs to prevent restcnosis that previously were shown 
to be effective in animal models also raises concerns about the 
validity of the animal models used to study the restenosis 
process. 3) Chan et al. (39) have found that cells from patients 
with restenosis (both restenotic lesion and undiseased vessels) 
showed significant lower sensitivity to growth inhibition by 
heparin than control cells (p c 0.001). This relative heparin 
resistance of human vascular smooth muscle cells may explain 
why pharmacologic agents that inhibit ncointimal proliferation 
in animal models have failed to prevent human vascular 
restenosis. In a recent study (40) low molecular weight heparin 
given in high doses has been ineffective in inhibiting smooth 
muscle cell proliferation in a baboon model of angioplasty. It is 
proposed that the lack of an effect in primates might reflect the 
presence of a heperin-insensitive pathway of smooth muscle 
cell activation, possibly through platelet-derived growth factor. 
4) Rcstcnosis is a multifactorial process, including such factors 
as vessel recoil and fibrotic contraction, and attempts to prevent 
it by a single agent focused on a single process may be inadequate. 
Acute t~ults. The administration of rcviparin as a bolus 
and infusion resulted in a 52% reduction in the composite 
acute event rate, primarily in the need for stent implantation as 
a rescue procedure and in the usc of autoperfusion balloon 
catheters. However, this finding must be counted as an addi- 
tional observation because early events and acute complica- 
tions of PTCA were not designed as an end point of the study. 
The rather low incidence of 3.9%. of early events in the present 
study is comparable to that found in the Hirudin in a European 
Restenosis Prevention Trial Versus Heparin Treatment in 
PTCA Patients (HELVETICA) study (41). which compared 
the effects of recombinant hirudin as an adjunctive therapy 
with angioplasty with placebo. A recent trial using a monoclo- 
nal antihdy directed against the platelet glycoprotein WIIa 
receptor (Evaluation of Ilb/llla Platelet Receptor Antagonist 
7E3 in Preventing Ischcmic Complications [EPIC] study [42]) 
suggested that platelet thromhrsis plays an important role in 
the abrupt closure of coronary lesions treated by angioplasty. 
The positive effect of reviparin on the early adverse outcome 
after PTCA may be due to improved antithrombotic properties 
compared with those of standard heparin (11.12). 
Conclusions. The ability of reviparin to inhibit vascular 
smooth muscle growth in vitro and to limit myointimal hypcr- 
plasia in animal models of vascular injury is well documented. 
However, in the present randomized, controlled study, revipa- 
rin given at a very early stage of vascular injury, in dosages 
equal to those used in the animal studies and administered for 
a sufficient length of time. did not reduce the incidence of clinical 
rcstcnosis. Explorativc analysis rcvcaled a 52% reduction in the 
acute-phase adverse outcome, revealing a diminished need for 
immediate subsequent coronary revascularization procedures 
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